Clenbuterol
Also known as: Clen, Clenbuterol Hydrochloride, Spiropent, Ventipulmin, Clenbuterolhydrochlorid
Bronchodilator used off-label for fat loss — raises metabolic rate modestly, at the cost of cardiac strain that is the actual reason for its reputation.
Substance family
They increase metabolic rate or mobilise fat through adrenergic and thermogenic mechanisms. Cardiac load is the shared limiting factor, and it adds up when they are combined.
Effects on
Which outcomes this substance acts on — descriptive, not a recommendation.
Strain profile
Where this substance is most likely to hit — a rough orientation, individually dependent on dose, duration and predisposition.
This substance causes
Dosing & protocols by goal
Rough orientation ranges as reported in harm-reduction literature — not an individual treatment plan. Doses are individual and open-ended; frequency depends on the ester or half-life.
Bronchodilation (approved indication)
MedicalDose
0.02–0.04 mg / day
Frequency
2× daily
Cycle length
Medically supervised
The approved use in respiratory disease. The doses used for fat loss are several times higher.
Fat loss — titrated
AdvancedDose
20 µg, raised by 20 µg every few days to 80–120 µg / day
Frequency
1–2× daily, in the morning
Cycle length
2 weeks on, 2 weeks off
TitrationTitrationAdjusting a dose stepwise against a measured result rather than setting it in advance. is not optional — starting at a high dose reliably produces tremor, palpitations and cramps. Take in the morning; the long half-lifehalf-lifeHow long it takes for half the substance to leave the body — it determines dosing frequency, not duration of effect. otherwise ruins sleep.
Higher doses
AdvancedDose
> 120 µg / day
Frequency
Varies
Cycle length
—
Cardiac side effects scale sharply while the metabolic effect does not. Cases of cardiac arrhythmia and hospitalisation are documented in this range.
Side effect & countermeasure
Typical problems and what you can do to reduce harm — at a glance. Does not replace medical monitoring.
Problem
Cardiac strain: palpitations, arrhythmia, elevated resting heart rate
Countermeasure
The defining risk of this substance and the reason for the strict dose limits. Animal data shows cardiac muscle changes with prolonged use. Measure resting heart rate daily; palpitations, chest tightness or irregular beats mean stop immediately, not reduce. Pre-existing cardiac conditions rule it out entirely. Where a beta blocker is used against the heart rate, nebivolol is the one that is beta-1 selective and therefore leaves the beta-2 fat-loss effect largely intact — but needing a second drug to tolerate the first is a dose problem, not a pulse problem.
Problem
Muscle cramps and tremor
Problem
Combining it with a diuretic
Countermeasure
This is the most dangerous combination clenbuterol appears in, and it happens routinely in the final week before a contest. Clenbuterol already depletes potassium and drives the heart hard; furosemide or hydrochlorothiazide strips out more potassium on top of that, in a dehydrated body. Low potassiumLow potassiumPotassium too low — the mechanism behind diuretic-related deaths in physique sport. plus sympathetic overdrive is the arrhythmia scenario behind documented deaths in physique sport. If a diuretic is in the plan, the stimulant is not.
Problem
Insomnia
Countermeasure
With a half-lifehalf-lifeHow long it takes for half the substance to leave the body — it determines dosing frequency, not duration of effect. of over a day, an evening dose still acts at night. Take in the morning only. Poor sleep undermines exactly the deficit the substance is meant to support. No sleep supplement overrides an active stimulant — melatonin in particular signals a time of day rather than sedating.
Problem
Loss of lean mass in a deficit
Countermeasure
The commonly claimed anabolic effect is not established in humans — it comes from livestock studies at doses far above human use. Keep protein high and resistance training running; clenbuterol does not protect muscle.
Problem
Receptor downregulation
Countermeasure
The effect fades after roughly two weeks as receptors desensitise. This is the reason for the 2-on/2-off pattern. Raising the dose to compensate increases cardiac risk without restoring the effect.
Problem
Overestimating the metabolic effect
Countermeasure
The rise in energy expenditure is modest — a few percent. Clenbuterol does not replace a deficit; it makes a small difference to one that already exists.
Overview
Clenbuterol is a beta-2 agonist, medically a bronchodilator for respiratory disease. In Germany it is available mainly as a veterinary medicine. Its use for fat loss is off-label throughout and rests on a real but modest effect on metabolic rate.
Its reputation in the scene is considerably larger than its effect. What is genuinely notable about clenbuterol is not how much fat it removes but how much strain it places on the heart while doing so.
Mechanism of Action
Clenbuterol binds to beta-2 adrenergic receptors, the same receptors adrenaline acts on. In the lungs this dilates the airways — the medical purpose. In fat and muscle tissue it raises thermogenesis and lipolysis, meaning energy expenditure and fat breakdown increase.
The scale matters for realistic expectations: the rise in total energy expenditure is in the low single-digit percentage range. That is not nothing over weeks, but it is far from what the substance is often credited with.
Beta receptors are also present in cardiac tissue. Clenbuterol is selective for beta-2 rather than beta-1, but selectivity is relative — at the doses used here, cardiac effects occur reliably. Elevated resting heart rate, palpitations and in some cases arrhythmia are the direct consequence. Animal studies additionally show structural changes to cardiac muscle with prolonged administration.
Receptors desensitise after roughly two weeks. This is why the effect fades and why the two-weeks-on, two-weeks-off pattern exists — not as a safety measure but because continuing simply stops working.
Typical Context
Clenbuterol is used in diet phases, titrated upward from twenty micrograms in steps of twenty every few days, to a range of eighty to a hundred and twenty micrograms daily.
Titration is the part most often skipped, and it is the part that determines tolerability. Starting at a high dose produces tremor, palpitations and cramps within hours. Working up gradually allows partial adaptation.
Two practical details matter more than they appear. Take it in the morning: with a half-life exceeding a day, an evening dose is still active at night, and the resulting insomnia works directly against the deficit. And supplement taurine — clenbuterol depletes it, and taurine deficiency is the direct cause of the cramps that so many people attribute to electrolytes alone.
The frequently claimed anabolic or muscle-sparing effect deserves a clear statement: it comes from livestock studies at doses far beyond human use and is not established in humans. Clenbuterol does not protect muscle in a deficit.
Side Effects & Risks
- Cardiac strain: elevated resting heart rate, palpitations, arrhythmia
- Structural cardiac muscle changes with prolonged use (animal data)
- Muscle cramps through taurine and potassium depletion
- Tremor, particularly in the hands
- Insomnia
- Restlessness, anxiety, sweating
- Headache
- Elevated blood pressure
Blood Work & Monitoring
- Resting heart rate — measured daily; the key marker for this substance
- Blood pressure — measured at home
- Electrolytes (potassium, magnesium) — depleted by the substance
- ECG — worth discussing with a doctor for repeated use
- Liver values (ALT, AST, GGT) — as a baseline
Harm-Reduction Notes
- Titrate up from 20 µg; do not start at the target dose
- Morning dosing only — the long half-life otherwise destroys sleep
- Supplement taurine (2–3 g daily) and keep potassium and magnesium adequate
- Palpitations, chest tightness or irregular heartbeat: stop immediately, do not reduce
- Not for anyone with a pre-existing cardiac condition or elevated blood pressure
- Maximum two weeks continuously; the effect fades regardless as receptors desensitise
- Do not combine with other stimulants — the cardiac effects add up
- It does not spare muscle; protein and training still carry that job
Legal status by region
Regulation differs considerably between jurisdictions and changes over time. This is a rough orientation, not legal advice — check the rules that apply where you are.
| Region | Regulatory status |
|---|---|
| United States | Prescription-only medicineApproved for defined indications; use outside them is off-label. |
| EU / UK | Prescription-only medicineApproved for defined indications. |
| Canada / Australia | Prescription-only medicine |
| Parts of Asia, Latin America & Middle East | Pharmacy availability variesSeveral countries dispense it without prescription in practice. Rules and enforcement differ and change. |
| Competitive sport | Check the current WADA listSome substances in this class are prohibited, others are not. |